|
|
|
%20PRIVATE%20LIMITED%20-%20498179%2021-Mar-2018_files/image015.jpg){kind=small}
%20PRIVATE%20LIMITED%20-%20498179%2021-Mar-2018_files/image016.jpg)
%20PRIVATE%20LIMITED%20-%20498179%2021-Mar-2018_files/image018.gif)
MIRA INFORM REPORT
|
Report No. : |
498179 |
|
Report Date : |
21.03.2018 |
IDENTIFICATION DETAILS
|
Name : |
SANOFI-SYNTHELABO
(INDIA) PRIVATE LIMITED (w.e.f. 28.05.2015) |
|
|
|
|
Formerly Known
As : |
SANOFI-SYNTHELABO
(INDIA) LIMITED |
|
|
|
|
Registered
Office : |
Sanofi House, CTS No.117-B, L and T Business Park, Saki Vihar Road, Powai, Mumbai – 400072, Maharashtra |
|
Tel. No.: |
91-22-28032000 |
|
|
|
|
Country : |
India |
|
|
|
|
Financials (as
on) : |
31.03.2017 |
|
|
|
|
Date of
Incorporation : |
25.10.2002 |
|
|
|
|
Com. Reg. No.: |
11-137682 |
|
|
|
|
Capital
Investment / Paid-up Capital : |
INR 331.400 Million |
|
|
|
|
CIN No.: [Company Identification
No.] |
U24230MH2002PTC137682 |
|
|
|
|
IEC No.: [Import-Export Code No.] |
0896006824 |
|
|
|
|
GSTN : [Goods & Service Tax
Registration No.] |
Not Divulged |
|
|
|
|
TAN No.: [Tax Deduction &
Collection Account No.] |
Not Available |
|
|
|
|
PAN No.: [Permanent Account No.] |
AACCS1421J |
|
|
|
|
Legal Form : |
Private Limited Liability Company |
|
|
|
|
Line of Business
: |
The Company is organised into four business segments: Product Business, Research and Development Activities, Animal Health and Other services. · The Pharmaceutical Business division of the company is engaged in manufacturing and trading of Pharmaceutical and Animal Health Products. · The Research and Development division provides research and development services. · The Animal Health division provides production and marketing activities of Merial, which offers a complete range of medicines and vaccines for a wide variety of animal species. ·
Other services mainly comprises Clinical
Research activity, etc. [Registered
Activity] |
|
|
|
|
No. of Employees
: |
Information denied by the management |
RATING & COMMENTS
(Mira Inform has adopted New Rating mechanism w.e.f. 23rd
January 2017)
|
MIRA’s Rating : |
A+ |
|
Credit Rating |
Explanation |
Rating Comments |
|
A+ |
Low Risk |
Business dealings permissible with low
risk of default |
|
Maximum Credit Limit : |
USD 12000000 |
|
|
|
|
Status : |
Excellent |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Clear |
|
|
|
|
Comments : |
Subject is a wholly owned subsidiary of “Sanofi S.A”, France. The
company was incorporated in the year 2002. It is engaged in manufacturing of pharmaceutical products. For the financial year 2017, the revenue of the company has increased
by 3.50% along with fair profit margin of 24.13%. The healthy financial profile of the company is marked by healthy
networth base along with strong debt coverage indicators due to debt free
balance sheet profile. Rating also takes into consideration strong financial and managerial
support that the company receives from its holding entity backed by its well
experienced management team. However, these rating strengths are partially offset by unfavourable
gap between trade payables and trade receivables. Business is active. Payment seems to be regular. In view of aforesaid, the company can be considered for business
dealings at usual trade terms and conditions. |
NOTES:
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List
|
Country Name |
Previous Rating (30.09.2017) |
Current Rating (31.12.2017) |
|
India |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low Risk |
A2 |
|
Moderately Low Risk |
B1 |
|
Moderate Risk |
B2 |
|
Moderately High Risk |
C1 |
|
High Risk |
C2 |
|
Very High Risk |
D |
EXTERNAL AGENCY RATING
NOT AVAILABLE
RBI DEFAULTERS’ LIST STATUS
Subject’s name is not enlisted as a defaulter
in the publicly available RBI Defaulters’ list.
EPF (Employee Provident Fund) DEFAULTERS’ LIST STATUS
Subject’s name is not enlisted as a defaulter
in the publicly available EPF (Employee Provident Fund) Defaulters’ list as of
31-03-2016.
BIFR (Board for Industrial & Financial Reconstruction) LISTING
STATUS
Subject’s name is not listed as a Sick Unit in
the publicly available BIFR (Board for Industrial & Financial
Reconstruction) list as of 21.03.2018
IBBI (Insolvency and Bankruptcy Board of India) LISTING STATUS
Subject’s name is not listed in the publicly
available IBBI (Insolvency and Bankruptcy Board of India) list as of report
date.
INFORMATION DENIED
Management Non-Cooperative (91-22-28032000)
LOCATIONS
|
Registered Office : |
Sanofi House, CTS No.117-B, L and T Business Park, Saki Vihar Road, Powai, Mumbai – 400072, Maharashtra, India |
|
Tel. No.: |
91-22-28278000 / 28032000 |
|
Fax No.: |
91-22-28370939 |
|
E-Mail : |
|
|
Website : |
|
|
|
|
|
Factory : |
Village 7 P.O. Indrad, Taluka Kadi, District: Mehsana, Gujarat, India |
DIRECTORS
AS ON 31.03.2017
|
Name : |
Mr. Lionel Jean Marie Guerin |
||||||||||||||||
|
Designation : |
Director |
||||||||||||||||
|
Address : |
901, 9th Floor, 30, Union Park, Khar (West), Mumbai – 400052,
Maharashtra, India |
||||||||||||||||
|
Date of Birth/Age : |
28.09.2015 |
||||||||||||||||
|
Date of Appointment : |
07232453 |
||||||||||||||||
|
DIN No.: |
|
||||||||||||||||
|
Other Directorship:
|
|||||||||||||||||
|
|
|
||||||||||||||||
|
Name : |
Mr. Narayanan Rajaram |
||||||||||||||||
|
Designation : |
Additional Director |
||||||||||||||||
|
Address : |
802,Evita, Hiranandani Gardens, Powai, Mumbai – 400076, Maharashtra,
India |
||||||||||||||||
|
DIN No.: |
01.01.2018 |
||||||||||||||||
|
DIN No.: |
02977405 |
||||||||||||||||
|
Other Directorship:
|
|||||||||||||||||
KEY EXECUTIVES
|
Name : |
Mr. Deepa Ramniklal Shah |
|
Designation : |
Company Secretary |
|
Address : |
12/4, Mathuradas Colony, Kalina, Santacruz (East), Mumbai –
400098, Maharashtra, India |
|
Date of Appointment : |
30.03.2017 |
|
PAN No.: |
DIUPS5891C |
MAJOR SHAREHOLDERS
AS ON 31.03.2017
|
Names of Shareholders |
|
No. of Shares |
|
Sanofi, France |
|
33142854 |
|
SPI, France |
|
1 |
|
Sanofi Development Pharma, France |
|
1 |
|
Sanofi Aventis Europe, France |
|
1 |
|
Sanofi Aventis Participations, France |
|
1 |
|
SECIPE, France |
|
1 |
|
Shailesh Ayyangar |
|
1 |
|
|
|
|
|
Total |
|
33142860 |
Equity Share Break up (Percentage of Total Equity)
AS ON 27.09.2017
|
Category |
Percentage |
|
Promoters [Bodies
corporate] |
100.00 |
|
Total |
100.00 |
%20PRIVATE%20LIMITED%20-%20498179%2021-Mar-2018_files/image020.gif)
BUSINESS DETAILS
|
Line of Business : |
The Company is organised into four business segments: Product Business, Research and Development Activities, Animal Health and Other services. · The Pharmaceutical Business division of the company is engaged in manufacturing and trading of Pharmaceutical and Animal Health Products. · The Research and Development division provides research and development services. · The Animal Health division provides production and marketing activities of Merial, which offers a complete range of medicines and vaccines for a wide variety of animal species. ·
Other services mainly comprises Clinical
Research activity, etc. [Registered
Activity] |
||||||||
|
|
|
||||||||
|
Products / Services
: |
|
||||||||
|
|
|
||||||||
|
Brand Names : |
Not Available |
||||||||
|
|
|
||||||||
|
Agencies Held : |
Not Available |
||||||||
|
|
|
||||||||
|
Exports : |
Not Divulged |
||||||||
|
|
|
||||||||
|
Imports : |
Not Divulged |
||||||||
|
|
|
||||||||
|
Terms : |
Not Divulged |
PRODUCTION STATUS – (NOT AVAILABLE)
GENERAL INFORMATION
|
Suppliers : |
|
||||||||||||||||||||||
|
|
|
||||||||||||||||||||||
|
Customers : |
|
||||||||||||||||||||||
|
|
|
||||||||||||||||||||||
|
No. of Employees : |
Information denied by the management |
||||||||||||||||||||||
|
|
|
||||||||||||||||||||||
|
Bankers : |
·
The Hongkong And Shanghai Banking Corporation
Limited · ING Vysya Bank Limited |
|
Auditors : |
|
|
Name : |
S R B C and Company LLP Chartered Accountants |
|
Address : |
14th
Floor, The Ruby, Senapati Bapat Marg, Dadar (West), Mumbai – 400028,
Maharashtra, India |
|
PAN No.: |
ACHFS9117R |
|
|
|
|
Memberships : |
Not Available |
|
|
|
|
Collaborators : |
Not Available |
|
|
|
|
Holding company : |
· Sanofi S.A, France |
|
|
|
|
Fellow
subsidiaries : |
· Aventis Pharma Limited, United Kingdom · Genzyme Corporation, United States · Sanofi India Limited, India · Sanofi US Services Inc., United States · Sanofi Winthrop Industrie SA, France · Sanofi-Aventis Groupe S.A, France · Sanofi-Aventis Lanka Limited, Sri Lanka · Sanofi-Aventis Singapore Pte. Limited, Singapore · Shantha Biotecnics Limited, India · Genzyme Europe B.V. · Sanofi-Aventis Pakistan limited · Sanofi Chemie · Sanofi Israel · Sanofi Pasteur India Private Limited · sanofi-aventis U.S.Inc. · Sanofi-Aventis Deutschland GmbH · Sanofi-Aventis Korea Co., Limited · Sanofi-Aventis Gulf FZE LLC · Merial Select, Inc. · Sanofi-Aventis Canada Inc. · Sanofi Lanka Limited · Sanofi Pasteur S. A. · Sanofi-Aventis Hong Kong Limited · sanofi-aventis S.p.A · Shantha Biotechnics Private Limited ·
Merial S.A.S |
CAPITAL STRUCTURE
AS ON 27.09.2017
Authorised Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
|
|
|
|
|
33150000 |
Equity Shares |
INR 10/- each |
INR 331.500 Million |
|
|
|
|
|
Issued, Subscribed & Paid-up Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
|
|
|
|
|
33142860 |
Equity Shares |
INR 10/- each |
INR 331.429 Million |
|
|
|
|
|
FINANCIAL DATA
[all figures are
in INR Million]
ABRIDGED
BALANCE SHEET (STANDALONE)
|
SOURCES OF FUNDS |
31.03.2017 |
31.03.2016 |
31.03.2015 |
|
I.
EQUITY
AND LIABILITIES |
|
|
|
|
(1)Shareholders' Funds |
|
|
|
|
(a) Share Capital |
331.400 |
331.400 |
331.400 |
|
(b) Reserves & Surplus |
3858.900 |
2791.000 |
2743.800 |
|
(c) Money
received against share warrants |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
(2) Share Application money pending
allotment |
0.000 |
0.000 |
0.000 |
|
Total
Shareholders’ Funds (1) + (2) |
4190.300 |
3122.400 |
3075.200 |
|
|
|
|
|
|
(3)
Non-Current Liabilities |
|
|
|
|
(a) Long-term borrowings |
0.000 |
0.000 |
0.000 |
|
(b) Deferred tax liabilities (Net) |
0.000 |
0.000 |
0.000 |
|
(c) Other long term
liabilities |
0.000 |
0.000 |
0.000 |
|
(d) Long-term
provisions |
145.400 |
131.900 |
101.700 |
|
Total Non-current
Liabilities (3) |
145.400 |
131.900 |
101.700 |
|
|
|
|
|
|
(4)
Current Liabilities |
|
|
|
|
(a) Short
term borrowings |
0.000 |
0.000 |
0.000 |
|
(b) Trade
payables |
482.800 |
499.400 |
449.200 |
|
(c) Other
current liabilities |
177.400 |
129.100 |
113.200 |
|
(d) Short-term
provisions |
158.700 |
144.300 |
103.500 |
|
Total Current
Liabilities (4) |
818.900 |
772.800 |
665.900 |
|
|
|
|
|
|
TOTAL |
5154.600 |
4027.100 |
3842.800 |
|
|
|
|
|
|
II.
ASSETS |
|
|
|
|
(1)
Non-current assets |
|
|
|
|
(a) Fixed
Assets |
|
|
|
|
(i)
Tangible assets |
305.600 |
321.800 |
348.500 |
|
(ii)
Intangible Assets |
523.800 |
12.800 |
691.300 |
|
(iii)
Capital work-in-progress |
68.800 |
5.000 |
8.200 |
|
(iv)
Intangible assets under development |
16.800 |
0.000 |
0.000 |
|
(b) Non-current Investments |
265.700 |
562.100 |
562.100 |
|
(c) Deferred tax assets (net) |
44.100 |
281.400 |
120.000 |
|
(d)
Long-term Loan and Advances |
151.800 |
166.600 |
163.900 |
|
(e) Other
Non-current assets |
0.000 |
0.000 |
0.000 |
|
Total Non-Current
Assets |
1376.600 |
1349.700 |
1894.000 |
|
|
|
|
|
|
(2)
Current assets |
|
|
|
|
(a)
Current investments |
0.000 |
0.000 |
0.000 |
|
(b) Inventories |
696.900 |
518.300 |
488.300 |
|
(c) Trade
receivables |
412.400 |
479.800 |
469.200 |
|
(d) Cash
and cash equivalents |
2591.800 |
1627.700 |
947.500 |
|
(e)
Short-term loans and advances |
70.200 |
44.700 |
36.400 |
|
(f) Other
current assets |
6.700 |
6.900 |
7.400 |
|
Total
Current Assets |
3778.000 |
2677.400 |
1948.800 |
|
|
|
|
|
|
TOTAL |
5154.600 |
4027.100 |
3842.800 |
PROFIT
& LOSS ACCOUNT (STANDALONE)
|
|
PARTICULARS |
31.03.2017 |
31.03.2016 |
31.03.2015 |
|
|
|
SALES |
|
|
|
|
|
|
|
Income |
4425.300 |
4275.700 |
4088.700 |
|
|
|
Other Income |
116.200 |
100.700 |
51.400 |
|
|
|
TOTAL |
4541.500 |
4376.400 |
4140.100 |
|
|
|
|
|
|
|
|
Less |
EXPENSES |
|
|
|
|
|
|
|
Cost of Materials Consumed |
606.300 |
475.600 |
554.000 |
|
|
|
Purchase of Stock-in-trade |
502.100 |
495.800 |
505.000 |
|
|
|
Changes in Inventories of finished goods, work-in-progress and
stock-in-trade |
(177.800) |
(95.000) |
124.600 |
|
|
|
Employee Benefits Expenses |
564.900 |
471.500 |
475.600 |
|
|
|
Exceptional items |
(1098.900) |
0.000 |
0.000 |
|
|
|
Other expenses |
2352.000 |
2043.100 |
2092.400 |
|
|
|
TOTAL |
2748.600 |
3391.000 |
3751.600 |
|
|
|
|
|
|
|
|
|
PROFIT/(LOSS)
BEFORE INTEREST, TAX, DEPRECIATION AND AMORTISATION |
1792.900 |
985.400 |
388.500 |
|
|
|
|
|
|
|
|
|
Less |
FINANCIAL
EXPENSES |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
|
|
PROFIT/(LOSS)
BEFORE TAX, DEPRECIATION AND AMORTISATION |
1792.900 |
985.400 |
388.500 |
|
|
|
|
|
|
|
|
|
Less |
DEPRECIATION/
AMORTISATION |
84.100 |
69.800 |
747.700 |
|
|
|
|
|
|
|
|
|
|
PROFIT/(LOSS)
BEFORE TAX |
1708.800 |
915.600 |
(359.200) |
|
|
|
|
|
|
|
|
|
Less |
TAX |
640.900 |
868.400 |
(2.100) |
|
|
|
|
|
|
|
|
|
|
PROFIT/(LOSS)
AFTER TAX |
1067.900 |
47.200 |
(357.100) |
|
|
|
|
|
|
|
|
|
|
Earnings /
(Loss) Per Share (INR) |
32.22 |
1.42 |
(12.36) |
|
CURRENT MATURITIES
OF LONG TERM DEBT DETAILS
|
Particulars |
31.03.2017 |
31.03.2016 |
31.03.2015 |
|
Current Maturities of Long term debt |
NA |
NA |
NA |
|
Cash generated from operations |
NA |
NA |
NA |
|
Net cash flow from (used in) operations |
1605.200 |
899.000 |
848.000 |
|
Net cash flows from (used in) operating activities |
1406.800 |
645.000 |
684.100 |
KEY
RATIOS
EFFICIENCY RATIOS
|
PARTICULARS |
31.03.2017 |
31.03.2016 |
31.03.2015 |
|
Average Collection Days (Sundry
Debtors / Income * 365 Days) |
34.01 |
40.96 |
41.89 |
|
|
|
|
|
|
Account Receivables Turnover (Income / Sundry Debtors) |
10.73 |
8.91 |
8.71 |
|
|
|
|
|
|
Average Payment Days (Sundry Creditors / Purchases * 365 Days) |
158.99 |
187.65 |
154.82 |
|
|
|
|
|
|
Inventory Turnover (Operating Income / Inventories) |
2.57 |
1.90 |
0.80 |
|
|
|
|
|
|
Asset Turnover (Operating Income / Net Fixed Assets) |
1.96 |
2.90 |
0.37 |
LEVERAGE RATIOS
|
PARTICULARS |
31.03.2017 |
31.03.2016 |
31.03.2015 |
|
Debt Ratio ((Borrowing
+ Current Liabilities) / Total Assets) |
0.16 |
0.19 |
0.17 |
|
|
|
|
|
|
Debt Equity Ratio (Total Liability / Networth) |
0.00 |
0.00 |
0.00 |
|
|
|
|
|
|
Current Liabilities to Networth (Current Liabilities / Net Worth) |
0.20 |
0.25 |
0.22 |
|
|
|
|
|
|
Fixed Assets to Networth (Net Fixed Assets / Networth) |
0.22 |
0.11 |
0.34 |
|
|
|
|
|
|
Interest Coverage Ratio (PBIT / Financial Charges) |
0.00 |
0.00 |
0.00 |
PROFITABILITY RATIOS
|
PARTICULARS |
|
31.03.2017 |
31.03.2016 |
31.03.2015 |
|
PAT to Sales ((PAT
/ Sales) * 100) |
% |
24.13 |
1.10 |
(8.73) |
|
|
|
|
|
|
|
Return on Total Assets ((PAT / Total Assets) * 100) |
% |
20.72 |
1.17 |
(9.29) |
|
|
|
|
|
|
|
Return on Investment (ROI) ((PAT / Networth) * 100) |
% |
25.49 |
1.51 |
(11.61) |
SOLVENCY RATIOS
|
PARTICULARS |
31.03.2017 |
31.03.2016 |
31.03.2015 |
|
Current Ratio (Current
Assets / Current Liabilities) |
4.61 |
3.46 |
2.93 |
|
|
|
|
|
|
Quick Ratio ((Current Assets – Inventories) / Current Liabilities) |
3.76 |
2.79 |
2.19 |
|
|
|
|
|
|
G-Score Ratio Financial (Networth / Total Assets) |
0.81 |
0.78 |
0.80 |
|
|
|
|
|
|
G-Score Ratio Debt (Debts / Equity Capital) |
0.00 |
0.00 |
0.00 |
|
|
|
|
|
|
G-Score Ratio Liquidity (Total Current Assets / Total Current Liabilities) |
4.61 |
3.46 |
2.93 |
Total
Liability = Short-term Debt + Long-term Debt + Current Maturities of Long-term
debts
FINANCIAL ANALYSIS
[all figures are
in INR Million]
DEBT EQUITY RATIO
|
Particular |
31.03.2015 |
31.03.2016 |
31.03.2017 |
|
|
(INR
In Million) |
(INR
In Million) |
(INR
In Million) |
|
Share Capital |
331.400 |
331.400 |
331.400 |
|
Reserves & Surplus |
2743.800 |
2791.000 |
3858.900 |
|
Net
worth |
3075.200 |
3122.400 |
4190.300 |
|
|
|
|
|
|
Long-term borrowings |
0.000 |
0.000 |
0.000 |
|
Short term borrowings |
0.000 |
0.000 |
0.000 |
|
Total
borrowings |
0.000 |
0.000 |
0.000 |
|
Debt/Equity
ratio |
0.000 |
0.000 |
0.000 |
%20PRIVATE%20LIMITED%20-%20498179%2021-Mar-2018_files/image022.gif)
YEAR-ON-YEAR GROWTH
|
Year
on Year Growth |
31.03.2015 |
31.03.2016 |
31.03.2017 |
|
|
(INR
In Million) |
(INR
In Million) |
(INR
In Million) |
|
Sales |
4088.700 |
4275.700 |
4425.300 |
|
|
|
4.574 |
3.499 |
%20PRIVATE%20LIMITED%20-%20498179%2021-Mar-2018_files/image024.gif)
NET PROFIT MARGIN
|
Net
Profit Margin |
31.03.2015 |
31.03.2016 |
31.03.2017 |
|
|
(INR
In Million) |
(INR
In Million) |
(INR
In Million) |
|
Sales |
4088.700 |
4275.700 |
4425.300 |
|
Profit/ (Loss) |
(357.100) |
47.200 |
1067.900 |
|
|
(8.73%) |
1.10% |
24.13% |
%20PRIVATE%20LIMITED%20-%20498179%2021-Mar-2018_files/image026.gif)
ABRIDGED
BALANCE SHEET (CONSOLIDATED)
|
SOURCES OF FUNDS |
|
31.03.2017 |
31.03.2016 |
|
I.
EQUITY
AND LIABILITIES |
|
|
|
|
(1)Shareholders' Funds |
|
|
|
|
(a) Share Capital |
|
331.400 |
331.400 |
|
(b) Reserves and Surplus |
|
3795.000 |
2748.600 |
|
(c) Money
received against share warrants |
|
0.000 |
0.000 |
|
(d) Minority interest |
|
0.000 |
0.000 |
|
|
|
|
|
|
(2) Share Application money pending
allotment |
|
0.000 |
0.000 |
|
Total
Shareholders’ Funds (1) + (2) |
|
4126.400 |
3080.000 |
|
|
|
|
|
|
(3)
Non-Current Liabilities |
|
|
|
|
(a) long-term borrowings |
|
0.000 |
0.000 |
|
(b) Deferred tax liabilities (Net) |
|
0.000 |
0.000 |
|
(c) Other long-term
liabilities |
|
0.000 |
0.000 |
|
(d) long-term
provisions |
|
145.400 |
131.900 |
|
Total Non-current
Liabilities (3) |
|
145.400 |
131.900 |
|
|
|
|
|
|
(4)
Current Liabilities |
|
|
|
|
(a) Short-term
borrowings |
|
0.000 |
0.000 |
|
(b) Trade
payables |
|
482.800 |
499.400 |
|
(c) Other
current liabilities |
|
177.400 |
129.100 |
|
(d) Short-term
provisions |
|
158.700 |
144.300 |
|
Total Current
Liabilities (4) |
|
818.900 |
772.800 |
|
|
|
|
|
|
TOTAL |
|
5090.700 |
3984.700 |
|
|
|
|
|
|
II.
ASSETS |
|
|
|
|
(1)
Non-current assets |
|
|
|
|
(a) Fixed
Assets |
|
|
|
|
(i)
Tangible assets |
|
305.600 |
321.800 |
|
(ii)
Intangible Assets |
|
523.800 |
12.800 |
|
(iii) Tangible assets
capital work-in-progress |
|
68.800 |
5.000 |
|
(iv)
Intangible assets under development |
|
16.800 |
0.000 |
|
(b) Non-current Investments |
|
201.800 |
519.700 |
|
(c) Deferred tax assets (net) |
|
44.100 |
281.400 |
|
(d)
Long-term
loans and advances |
|
151.800 |
166.600 |
|
(e) Other Non-current
assets |
|
0.000 |
0.000 |
|
Total Non-Current
Assets |
|
1312.700 |
1307.300 |
|
|
|
|
|
|
(2)
Current assets |
|
|
|
|
(a)
Current investments |
|
0.000 |
0.000 |
|
(b)
Inventories |
|
696.900 |
518.300 |
|
(c) Trade
receivables |
|
412.400 |
479.800 |
|
(d) Cash and bank
balances |
|
2591.800 |
1627.700 |
|
(e)
Short-term loans and advances |
|
70.200 |
44.700 |
|
(f) Other
current assets |
|
6.700 |
6.900 |
|
Total
Current Assets |
|
3778.000 |
2677.400 |
|
|
|
|
|
|
TOTAL |
|
5090.700 |
3984.700 |
PROFIT
& LOSS ACCOUNT (CONSOLIDATED)
|
|
PARTICULARS |
|
31.03.2017 |
31.03.2016 |
|
|
SALES |
|
|
|
|
|
Total
Revenue from operations |
|
4425.300 |
4275.700 |
|
|
Other Income |
|
116.200 |
100.700 |
|
|
TOTAL |
|
4541.500 |
4376.400 |
|
|
|
|
|
|
|
Less |
EXPENSES |
|
|
|
|
|
Cost of Materials
Consumed |
|
606.300 |
475.600 |
|
|
Purchases of
Stock-in-Trade |
|
502.100 |
495.800 |
|
|
Changes in inventories of
finished goods, work-in-progress and Stock-in-Trade |
|
(177.800) |
(95.000) |
|
|
Employee benefit expense |
|
564.900 |
471.500 |
|
|
Other expenses |
|
2352.000 |
2043.100 |
|
|
Exceptional items |
|
(1098.900) |
0.000 |
|
|
TOTAL |
|
2748.600 |
3391.000 |
|
|
|
|
|
|
|
|
PROFIT/
(LOSS) BEFORE INTEREST, TAX,
DEPRECIATION AND AMORTISATION |
|
1792.900 |
985.400 |
|
|
|
|
|
|
|
Less |
FINANCIAL
EXPENSES |
|
0.000 |
0.000 |
|
|
|
|
|
|
|
|
PROFIT / (LOSS) BEFORE TAX, DEPRECIATION AND AMORTISATION |
|
1792.900 |
985.400 |
|
|
|
|
|
|
|
Less/ Add |
DEPRECIATION/
AMORTISATION |
|
84.100 |
69.800 |
|
|
|
|
|
|
|
|
PROFIT/ (LOSS)
BEFORE TAX |
|
1708.800 |
915.600 |
|
|
|
|
|
|
|
Less |
TAX |
|
495.300 |
39.500 |
|
|
|
|
|
|
|
|
PROFIT/ (LOSS)
AFTER TAX |
|
1213.500 |
876.100 |
|
|
|
|
|
|
|
Less/ Add |
SHARE
OF PROFIT (LOSS) OF ASSOCIATES |
|
(21.500) |
(34.200) |
|
|
|
|
|
|
|
|
TOTAL PROFIT
(LOSS) FOR PERIOD |
|
1046.400 |
13.000 |
|
|
|
|
|
|
|
|
Earnings / (Loss) Per
Share (INR) |
|
32.22 |
1.42 |
LOCAL AGENCY FURTHER INFORMATION
|
Sr. No. |
Check list by
info agents |
Available in
Report (Yes/No) |
|
1 |
Year of establishment |
Yes |
|
2 |
Constitution of the entity -Incorporation
details |
Yes |
|
3 |
Locality of the entity |
Yes |
|
4 |
Premises details |
No |
|
5 |
Buyer visit details |
-- |
|
6 |
Contact numbers |
Yes |
|
7 |
Name of the person contacted |
No |
|
8 |
Designation of contact person |
No |
|
9 |
Promoter’s background |
Yes |
|
10 |
Date of Birth of Proprietor / Partners /
Directors |
Yes |
|
11 |
Pan Card No. of Proprietor / Partners |
No |
|
12 |
Voter Id Card No. of Proprietor / Partners |
No |
|
13 |
Type of business |
Yes |
|
14 |
Line of Business |
Yes |
|
15 |
Export/import details (if applicable) |
No |
|
16 |
No. of employees |
No |
|
17 |
Details of sister concerns |
Yes |
|
18 |
Major suppliers |
No |
|
19 |
Major customers |
No |
|
20 |
Banking Details |
Yes |
|
21 |
Banking facility details |
No |
|
22 |
Conduct of the banking account |
-- |
|
23 |
Financials, if provided |
Yes |
|
24 |
Capital in the business |
Yes |
|
25 |
Last accounts filed at ROC, if applicable |
Yes |
|
26 |
Turnover of firm for last three years |
Yes |
|
27 |
Reasons for variation <> 20% |
-- |
|
28 |
Estimation for coming financial year |
No |
|
29 |
Profitability for last three years |
Yes |
|
30 |
Major shareholders, if available |
Yes |
|
31 |
External Agency Rating, if available |
No |
|
32 |
Litigations that the firm/promoter
involved in |
-- |
|
33 |
Market information |
-- |
|
34 |
Payments terms |
No |
|
35 |
Negative Reporting by Auditors in the
Annual Report |
No |
SEGMENT:
The Company is organised into four business segments: Product Business, Research & Development Activities, Animal Health and Other services. The Pharmaceutical Business division of the company is engaged in manufacturing and trading of Pharmaceutical and Animal Health Products. The Research and Development division provides research and development services. The Animal Health division provides production and marketing activities of Merial, which offers a complete range of medicines and vaccines for a wide variety of animal species and other services mainly comprises Clinical Research activity, etc.
Transactions with Boehringer Ingelheim
India Private Limited: [TGP1]
Sanofi Group and Boehringer Ingelheim India Private Limited have reached definitive agreements on June 27, 2016 to swap Sanofis Animal Health and Boehringer Ingelheims Consumer Healthcare businesses.
In connection with the global agreement the Board of Directors of Sanofi-Synthelabo India Private Limited, approved slump sale of Animal health care business to Boehringer Ingelheim in its meeting held on 26th July 2016. Board of Directors of Sanofi Synthelabo India Private Limited also approved purchase of consumer healthcare business from Boehringer Ingelheim India Private Limited.
In pursuance of both approvals 28th February, 2017, Sanofi Synthelabo India Private Limited enters into agreement with BI for the sale of its animal business on a going concern basis for a lumpsum consideration of INR 1554.900 million. The transaction has been recorded as per accounting standards issued by ICAI. The difference between sales proceeds and net book value of the assets pertaining animal business is recorded as profit from sale of the transaction.
On 28th Febuarary, 2017 Sanofi Synthelabo India Private Limited also enters into a second agreement with Boehringer Ingelheim India Private Limited for the purchase of Consumer Healthcare businesses for a consideration of INR 604.900 million. The transaction has been recorded as per accounting standards issued by ICAI. The difference between purchase price and net book value of tangible assets pertaining Consumer Healthcare business is recorded as intangible assets and Goodwill.
Amalgamation
of Genzyme India Private Limited and Merial India Private Limited with the Company
During the financial year ended 31st March 2016, on approval from the Board of Directors and Members, the Company filed a composite scheme of amalgamation with the Hon'ble High Court of Bombay, Maharashtra for amalgamation of the Company with Sanofi-Synthelabo (India) Private Limited pursuant to Section 391 to 394 of the Companies Act, 1956 and the corresponding provisions of the Companies Act, 2013, upon their notification (including any statutory modification(s) or re-enactment(s) thereof). On 29th November, 2016, the Company received sanction of said composite scheme of amalgamation from the Hon'ble High Court of Bombay, Maharashtra. The amalgamation was subject to regulatory approvals including approval of Foreign Investment Promotion Board (FIPB). The Board of Directors of Sanofi-Synthelabo (India) Private Limited took a decision at its meeting held on 7th June 2017 to discontinue process of this amalgamation due to other strategic priorities and the required FIPB process was stalled. The Board of Directors of the Company noted this decision at its meeting held on 20th June 2017 and decided that the amalgamation process of the Company with Sanofi-Synthelabo (India) Private Limited be discontinued with immediate effect.
INDEX OF CHARGES: NO
CHARGES EXISTS FOR COMPANY
FIXED ASSETS:
·
Land
·
Building
·
Plant and Machinery
·
Furniture and Fixture
·
Office Equipment
·
Computer
·
Vehicles
CMT REPORT (Corruption, Money Laundering & Terrorism]
The Public Notice information has been collected from various sources
including but not limited to: The Courts,
1] INFORMATION ON
DESIGNATED PARTY
No records exist designating subject or any of its beneficial owners, controlling
shareholders or senior officers as terrorist or terrorist organization or whom
notice had been received that all financial transactions involving their assets
have been blocked or convicted, found guilty or against whom a judgement or
order had been entered in a proceedings for violating money-laundering,
anti-corruption or bribery or international economic or anti-terrorism sanction
laws or whose assets were seized, blocked, frozen or ordered forfeited for
violation of money laundering or international anti-terrorism laws.
2] Court Declaration :
No records exist to suggest that subject is
or was the subject of any formal or informal allegations, prosecutions or other
official proceeding for making any prohibited payments or other improper payments
to government officials for engaging in prohibited transactions or with
designated parties.
3] Asset Declaration :
No records exist to suggest that the property or assets of the subject
are derived from criminal conduct or a prohibited transaction.
4] Record on Financial
Crime :
Charges or conviction
registered against subject: None
5] Records on Violation of
Anti-Corruption Laws :
Charges or
investigation registered against subject: None
6] Records on Int’l
Anti-Money Laundering Laws/Standards :
Charges or
investigation registered against subject: None
7] Criminal Records
No
available information exist that suggest that subject or any of its principals
have been formally charged or convicted by a competent governmental authority for
any financial crime or under any formal investigation by a competent government
authority for any violation of anti-corruption laws or international anti-money
laundering laws or standard.
8] Affiliation with
Government :
No record
exists to suggest that any director or indirect owners, controlling
shareholders, director, officer or employee of the company is a government
official or a family member or close business associate of a Government
official.
9] Compensation Package :
Our market
survey revealed that the amount of compensation sought by the subject is fair
and reasonable and comparable to compensation paid to others for similar
services.
10] Press Report :
No press reports / filings exists on
the subject.
CORPORATE GOVERNANCE
MIRA INFORM as part of its Due Diligence do provide comments on
Corporate Governance to identify management and governance. These factors often
have been predictive and in some cases have created vulnerabilities to credit
deterioration.
Our Governance Assessment focuses principally on the interactions
between a company’s management, its Board of Directors, Shareholders and other
financial stakeholders.
CONTRAVENTION
Subject is not known to have contravened any existing local laws, regulations
or policies that prohibit, restrict or otherwise affect the terms and
conditions that could be included in the agreement with the subject.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
INR |
|
US Dollar |
1 |
INR 65.04 |
|
|
1 |
INR 90.56 |
|
Euro |
1 |
INR 79.78 |
INFORMATION DETAILS
|
Information
Gathered by : |
GYT |
|
|
|
|
Analysis Done by
: |
VAR |
|
|
|
|
Report Prepared
by : |
NKT |
SCORE FACTORS
|
DEMERIT POINTS |
|
|
|
--BANK CHARGES |
YES/NO |
NO |
|
--LITIGATION |
YES/NO |
NO |
|
--OTHER ADVERSE INFORMATION |
YES/NO |
NO |
|
MERIT POINTS |
|
|
|
--SOLE DISTRIBUTORSHIP |
YES/NO |
NO |
|
--EXPORT ACTIVITIES |
YES/NO |
NO |
|
--AFFILIATION |
YES/NO |
YES |
|
--LISTED |
YES/NO |
NO |
|
--OTHER MERIT FACTORS |
YES/NO |
YES |
RATING EXPLANATIONS
|
Credit Rating |
Explanation |
Rating Comments |
|
A++ |
Minimum Risk |
Business dealings permissible with minimum
risk of default |
|
A+ |
Low Risk |
Business dealings permissible with low
risk of default |
|
A |
Acceptable Risk |
Business dealings permissible with
moderate risk of default |
|
B |
Medium Risk |
Business dealings permissible on a regular
monitoring basis |
|
C |
Medium High Risk |
Business dealings permissible preferably
on secured basis |
|
D |
High Risk |
Business dealing not recommended or on
secured terms only |
|
NB |
New Business |
No recommendation can be done due to
business in infancy stage |
|
NT |
No Trace |
No recommendation can be done as the
business is not traceable |
NB is stated where there is insufficient information to facilitate rating. However, it is not to be considered as unfavourable.
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major
sections of this report. The assessed factors are as follows:
·
Financial
condition covering various ratios
·
Company
background and operations size
·
Promoters
/ Management background
·
Payment
record
·
Litigation
against the subject
·
Industry
scenario / competitor analysis
·
Supplier
/ Customer / Banker review (wherever available)
This report is issued at
your request without any risk and responsibility on the part of MIRA INFORM
PRIVATE LIMITED (MIPL) or its officials.